Drug Screening & Pharmacology Services
High-throughput compound efficacy evaluation, toxicity profiling, and DMPK studies using physiologically relevant organoid models for accelerated drug discovery.
Accelerate Drug Discovery with Organoid-Based Platforms
Our platforms support single-agent and combination screening with comprehensive data analysis, enabling better prediction of in vivo outcomes than traditional 2D assays.
High-Throughput Screening (HTS)
96/384-well formats, automated liquid handling, capacity of 10,000+ compounds per campaign. Rapid screening of large compound libraries.
Efficacy Evaluation
Dose-response analysis, IC50/EC50 determination across multiple cancer subtypes and normal tissue controls. Comprehensive 8-point concentration ranges.
Combination Drug Screening
Matrix synergy identification, Bliss independence and Loewe additivity analysis, clinically relevant combination regimens.
Toxicity & Safety Assessment
Early hepatotoxicity, cardiotoxicity, and nephrotoxicity evaluation using liver, cardiac, and kidney organoid models.
DMPK & ADME Profiling
Drug metabolism and pharmacokinetic studies; permeability, metabolic stability, and drug-drug interaction assessment.
Mechanism of Action
Pathway analysis, target engagement confirmation, and resistance mechanism investigation using genomic and transcriptomic readouts.
Screening Workflow
Organoid Seeding
Standardized organoid preparation; seeding into 96/384-well plates; 24h recovery period.
Drug Treatment
Serial dilutions prepared; automated compound dispensing; treatment initiation.
Incubation
3-7 day incubation per protocol; intermediate imaging if required.
Readout
Cell viability, high-content imaging, or functional endpoint assays.
Data Analysis
IC50 calculation; synergy scoring; comprehensive report with recommendations.
Key Applications
Ready to Screen Your Compounds?
Contact our pharmacology team to design a customized screening campaign tailored to your drug discovery needs.
Start Your Drug Screening Project